全文获取类型
收费全文 | 486篇 |
免费 | 25篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 25篇 |
妇产科学 | 10篇 |
基础医学 | 48篇 |
口腔科学 | 11篇 |
临床医学 | 65篇 |
内科学 | 150篇 |
皮肤病学 | 9篇 |
神经病学 | 26篇 |
特种医学 | 43篇 |
外科学 | 54篇 |
综合类 | 22篇 |
预防医学 | 23篇 |
眼科学 | 3篇 |
药学 | 27篇 |
肿瘤学 | 11篇 |
出版年
2018年 | 4篇 |
2016年 | 5篇 |
2015年 | 14篇 |
2014年 | 15篇 |
2013年 | 13篇 |
2012年 | 9篇 |
2011年 | 6篇 |
2010年 | 29篇 |
2009年 | 20篇 |
2008年 | 7篇 |
2007年 | 18篇 |
2006年 | 5篇 |
2005年 | 8篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 8篇 |
1998年 | 29篇 |
1997年 | 18篇 |
1996年 | 25篇 |
1995年 | 12篇 |
1994年 | 12篇 |
1993年 | 15篇 |
1992年 | 5篇 |
1991年 | 12篇 |
1990年 | 6篇 |
1989年 | 15篇 |
1988年 | 14篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1972年 | 3篇 |
1962年 | 3篇 |
1959年 | 15篇 |
1958年 | 16篇 |
1957年 | 14篇 |
1956年 | 10篇 |
1955年 | 15篇 |
1954年 | 19篇 |
1952年 | 5篇 |
1949年 | 3篇 |
1948年 | 4篇 |
排序方式: 共有530条查询结果,搜索用时 31 毫秒
111.
In the absence of conclusive assays capable of determining the functionality of ex vivo expanded human hematopoietic progenitor cells, we combined cell tracking with the membrane dye PKH2, immunostaining for CD34, and limiting dilution analysis to estimate the frequency of long-term hematopoietic culture-initiating cells (LTHC-ICs) among de novo-generated CD34+ cells. Umbilical cord blood (CB) and bone marrow (BM) CD34+ cells were stained with PKH2 on day 0 and cultured with stem cell factor (SCF) and interleukin-3 (IL-3) in short-term stromal cell- free suspension cultures. Proliferation of CD34+ cells in culture was tracked through their PKH2 fluorescence relative to day 0 and the continued expression of CD34. As such, it was possible to identify cells that had divided while maintaining the expression of CD34 (CD34+PKH2dim) and others that expressed CD34 but had not divided (CD34+PKH2bright). In all such cultures, a fraction of both BM and CB CD34+ cells failed to divide in response to cytokines and persisted in culture for up to 10 days as CD34+PKH2bright cells. Between days 5 and 7 of culture, CD34+PKH2bright and CD34+PKH2dim cells were sorted in a limiting dilution scheme into 96-well plates prepared with medium, SCF, IL-3, IL-6, granulocyte-macrophage colony-stimulating factor, and erythropoietin. Cells proliferating in individual wells were assayed 2 weeks later for their content of clonogenic progenitors and the percentage of negative wells was used to calculate the frequency of LTHC-ICs in each population. Among fresh isolated BM and CB CD34+ cells, the frequencies of LTHC-ICs were 2.01% +/- 0.98% (mean +/- SEM) and 7.56% +/- 2.48%, respectively. After 5 to 7 days in culture, 3.00% +/- 0.56% of ex vivo-expanded BM CD34+PKH2bright cells and 4.46% +/- 1.10% of CD34+PKH2dim cells were LTHC-ICs. In contrast, the frequency of LTHC-IC in ex vivo expanded CB CD34+ cells declined drastically, such that only 3.87% +/- 2.06% of PKH2bright and 2.29% +/- 1.75% of PKH2dim cells were determined to be initiating cells after 5 to 7 days in culture. However, when combined with a calculation of the net change in the number of CD34+ cells in culture, the sum total of LTHC-ICs in both BM and CB cells declined in comparison to fresh isolated cells, albeit to a different degree between the two tissues.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
112.
The paper aims to determine whether the inflammation,a powerful risk factor that has been demonstrated for the development of coronary artery disease,plays a role in no-reflow phenomenon in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).Methods We prospectively analyzed 656 patients with AMI after primary PCI.Based on post-PCI angiography data,patients were divided into two groups:the no-reflow group (TIMI=2,n =60) and the reflow group (TIMI=3,n =596).Results Our results showed that the inflammatory factors including leukocyte count (×109/L) (10.90±4.04 vs.9.12±2.98 P =0.002),hs-CRP (5.04±0.71 vs.4.70±0.75 P =0.001) and other factor platelet count (×109/L) (210.96±33.42 vs.196.41±46.06 P =0.033) in no-reflow group are significantly higher than those in reflow group,major adverse cardiac events happened in the patients with no-reflow are higher than in reflow patients no matter in hospital or at the end of follow-up.We also found the left ventricular ejection fraction (LVEF) dramatically decreased (58.65±9.34 vs.51.29±11.38,P<0.001) and left ventricular end-diastolic dimension (LVEDD) significantly increased (49.94±6.75 mm vs.54.66±6.68mm,P<0.001) in no-reflow patients at the end of follow-up.Conclusions Our results suggest that inflammation factors function in no-reflow phenomenon,and no-reflow is a serious complication after primary PCI which predicts poor left ventricular systolic functional recovery and mortality in patients with AMI.(J Geriatr Cardiol 2008;5:217-222) 相似文献
113.
A prominent clinical manifestation of sickle cell disease (SCD) is hemolytic anemia. Although complement activation can lead to intravascular hemolysis, its role in the hemolysis of SCD is not known. Because normal red blood cells induced to vesiculate by treatment with calcium and ionophore become sensitive to damage by activated complement and because sickle cells release microvesicles as they circulate, we postulated that sickle cells might also be unusually sensitive to complement-dependent hemolysis. Complement activation is tightly regulated on the membrane of the normal erythrocyte; therefore, defective complement regulation by the sickle cell would be necessary for complement-dependent hemolysis to occur. These studies show a defect in the regulation of membrane attack complex (C5b-9) formation in sickle erythrocytes, particularly in the most dense cells. The defect is characterized by increased binding of C5b-7 and of C9 to denser sickle cells and results in increased susceptibility of sickle cells to C5b-9-mediated (reactive) lysis initiated by either C5b6 or activated cobra venom factor. Among the densest sickle cells, irreversibly sickled cells are especially sensitive to reactive lysis. The similarity of this defect to that previously described in a patient with paroxysmal nocturnal hemoglobinuria suggests that complement- mediated hemolysis could play a role in the anemia of SCD. 相似文献
114.
AC Justice KA McGinnis M Skanderson CC Chang CL Gibert MB Goetz D Rimland MC Rodriguez‐Barradas KK Oursler ST Brown RS Braithwaite M May KE Covinsky MS Roberts SL Fultz KJ Bryant for the VACS Project Team 《HIV medicine》2010,11(2):143-151
Background
As those with HIV infection live longer, ‘non‐AIDS’ condition associated with immunodeficiency and chronic inflammation are more common. We ask whether ‘non‐HIV’ biomarkers improve differentiation of mortality risk among individuals initiating combination antiretroviral therapy (cART).Methods
Using Poisson models, we analysed data from the Veterans Aging Cohort Study (VACS) on HIV‐infected veterans initiating cART between 1 January 1997 and 1 August 2002. Measurements included: HIV biomarkers (CD4 cell count, HIV RNA and AIDS‐defining conditions); ‘non‐HIV’ biomarkers (haemoglobin, transaminases, platelets, creatinine, and hepatitis B and C serology); substance abuse or dependence (alcohol or drug); and age. Outcome was all cause mortality. We tested the discrimination (C statistics) of each biomarker group alone and in combination in development and validation data sets, over a range of survival intervals, and adjusting for missing data.Results
Of veterans initiating cART, 9784 (72%) had complete data. Of these, 2566 died. Subjects were middle‐aged (median age 45 years), mainly male (98%) and predominantly black (51%). HIV and ‘non‐HIV’ markers were associated with each other (P<0.0001) and discriminated mortality (C statistics 0.68–0.73); when combined, discrimination improved (P<0.0001). Discrimination for the VACS Index was greater for shorter survival intervals [30‐day C statistic 0.86, 95% confidence interval (CI) 0.80–0.91], but good for intervals of up to 8 years (C statistic 0.73, 95% CI 0.72–0.74). Results were robust to adjustment for missing data.Conclusions
When added to HIV biomarkers, ‘non‐HIV’ biomarkers improve differentiation of mortality. When evaluated over similar intervals, the VACS Index discriminates as well as other established indices. After further validation, the VACS Index may provide a useful, integrated risk assessment for management and research. 相似文献115.
ST Sonis 《Oral diseases》2010,16(7):597-600
Oral Diseases (2010) 16 , 597–600 It has been slightly more than a decade since the classic mechanistic paradigm that defined the pathogenesis of mucositis was revised. A five‐stage sequence of linked biological events forms the basis for our current understanding of how regimen‐related mucosal injury occurs. The first stage is the initiation phase, although the gateway to toxicity has been the least studied. This essay proposes new thoughts on the phase’s components, how they might interact, and how they present new opportunities for treatment interventions and mucositis risk prediction. 相似文献
116.
目的分析介入诊疗过程中发生严重并发症的原因,探讨减少严重并发症发生的方法。方法通过对2000例介入诊疗病例的回顾性的调查统计,筛选出发生严重并发症病例,加以分析研究。结果2000例介入诊疗病例,共发生严重并发症23例,占1.15%。其中,截瘫1例,下肢动脉栓塞2例,严重的中枢神经系统并发症3例,急性心包填塞1例,急性肺水肿3例,消化道大出血2例,急性喉炎2例,肠梗阻3例,胆汁漏1例,严重顽固性感染2例,严重骨髓抑制1例,心脏停止跳动2例。结论介入诊疗严重并发症的发生原因是多方面的,病人个体差异很大,术前认真分析病人的具体情况,术中规范操作,术后严密观察病情变化及时处理,可以把并发症的发生和危害减少到最小程度。 相似文献
117.
MICHEL HAÏSSAGUERRE M.D. STÉPHANIE CHATEL M.S. FREDERIC SACHER M.D. RUKSHEN WEERASOORIYA M.D. VINCENT PROBST M.D. Ph.D. GILDAS LOUSSOUARN Ph.D. M.D. MARC HORLITZ M.D. RUEDIGE LIERSCH M.D. Ph.D. ERIC SCHULZE‐BAHR M.D. Ph.D. ARTHUR WILDE M.D. Ph.D. STEFAN KÄÄB M.D. Ph.D. JOSEPH KOSTER Ph.D. YORAM RUDY Ph.D. HERVÉ LE MAREC M.D. Ph.D. JEAN JACQUES SCHOTT Ph.D. 《Journal of cardiovascular electrophysiology》2009,20(1):93-98
Background: Early repolarization in the inferolateral leads has been recently recognized as a frequent syndrome associated with idiopathic ventricular fibrillation (VF). We report the case of a patient presenting dramatic changes in the ECG in association with recurrent VF in whom a novel genetic variant has been identified.
Case Report: This young female (14 years) was resuscitated in 2001 following an episode of sudden death due to VF. All examinations including coronary angiogram with ergonovine injection, MRI, and flecainide or isoproterenol infusion were normal. The patient had multiple (>100) recurrences of VF unresponsive to beta-blockers, lidocaine/mexiletine, verapamil, and amiodarone. Recurrences of VF were associated with massive accentuation of the early repolarization pattern at times mimicking acute myocardial ischemia. Coronary angiography during an episode with 1.2 mV J/ST elevation was normal. Isoproterenol infusion acutely suppressed electrical storms, while quinidine eliminated all recurrences of VF and restored a normal ECG over a follow-up of 65 months. Genomic DNA sequencing of KATP channel genes showed missense variant in exon 3 (NC_000012) of the KCNJ8 gene, a subunit of the KATP channel, conferring predisposition to dramatic repolarization changes and ventricular vulnerability. 相似文献
Case Report: This young female (14 years) was resuscitated in 2001 following an episode of sudden death due to VF. All examinations including coronary angiogram with ergonovine injection, MRI, and flecainide or isoproterenol infusion were normal. The patient had multiple (>100) recurrences of VF unresponsive to beta-blockers, lidocaine/mexiletine, verapamil, and amiodarone. Recurrences of VF were associated with massive accentuation of the early repolarization pattern at times mimicking acute myocardial ischemia. Coronary angiography during an episode with 1.2 mV J/ST elevation was normal. Isoproterenol infusion acutely suppressed electrical storms, while quinidine eliminated all recurrences of VF and restored a normal ECG over a follow-up of 65 months. Genomic DNA sequencing of K
118.
119.
Constance Flamand‐Rouvière ST Emilie Guettard MD Caroline Moreau MD Nadia Bahi‐Buisson MD PHD Vassili Valayannopoulos MD David Grabli MD PHD Jacques Motte MD PHD Diana Rodriguez MD PHD Agathe Roubertie MD PHD Lisa Maintigneux ST Isabelle Kemlin MD Irène Ceballos‐Picot PHARMD PHD David Adams MD PHD Marie Vidailhet MD Emmanuel Roze MD PHD 《Movement disorders》2010,25(11):1605-1611
120.